CU23938B1 - Moléculas de unión humanas capaces de neutralizar el virus de la influenza h3n2 - Google Patents
Moléculas de unión humanas capaces de neutralizar el virus de la influenza h3n2Info
- Publication number
- CU23938B1 CU23938B1 CU2011000206A CU20110206A CU23938B1 CU 23938 B1 CU23938 B1 CU 23938B1 CU 2011000206 A CU2011000206 A CU 2011000206A CU 20110206 A CU20110206 A CU 20110206A CU 23938 B1 CU23938 B1 CU 23938B1
- Authority
- CU
- Cuba
- Prior art keywords
- influenza virus
- antibodies
- neutralizing
- influenza
- molecules capable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se relaciona con moléculas de unión, tales como anticuerpos monoclonales humanos que se unen a distintos virus de la influenza que comprende HA del subtipo H3, tales como H3N2, y que tienen una amplia actividad neutralizante contra dicho virus de la influenza. Se proveen moléculas de ácido nucleico que codifican los anticuerpos, sus secuencias y composiciones que los comprenden y métodos para identificarlos y producirlos. Los anticuerpos se pueden usar en el diagnóstico, profilaxis y/o tratamiento de una infección por el virus de la influenza H3N2. En una realización preferida, los anticuerpos proveen protección cruzada contra distintos subtipos, de modo tal que se pueden prevenir y/o tratar infecciones por subtipos de influenza basados en H3, H7, y/o H10.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21589009P | 2009-05-11 | 2009-05-11 | |
| EP09159947 | 2009-05-11 | ||
| EP10151155 | 2010-01-20 | ||
| PCT/EP2010/056217 WO2010130636A1 (en) | 2009-05-11 | 2010-05-06 | Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20110206A7 CU20110206A7 (es) | 2012-10-15 |
| CU23938B1 true CU23938B1 (es) | 2013-08-29 |
Family
ID=42271865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2011000206A CU23938B1 (es) | 2009-05-11 | 2011-11-11 | Moléculas de unión humanas capaces de neutralizar el virus de la influenza h3n2 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8470327B2 (es) |
| EP (1) | EP2430046B1 (es) |
| JP (2) | JP5813629B2 (es) |
| KR (1) | KR101790354B1 (es) |
| CN (2) | CN102448986B (es) |
| AR (1) | AR076570A1 (es) |
| AU (1) | AU2010247530B2 (es) |
| BR (1) | BRPI1012749B1 (es) |
| CA (1) | CA2761648C (es) |
| CU (1) | CU23938B1 (es) |
| EA (1) | EA029939B8 (es) |
| ES (1) | ES2934102T3 (es) |
| IL (1) | IL216222A (es) |
| MX (1) | MX2011011331A (es) |
| MY (1) | MY183517A (es) |
| NZ (1) | NZ596032A (es) |
| SG (1) | SG176003A1 (es) |
| TW (1) | TWI589300B (es) |
| WO (1) | WO2010130636A1 (es) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
| CA2663388C (en) | 2006-09-07 | 2017-01-17 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| EP3524619A1 (en) | 2007-12-06 | 2019-08-14 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
| CA2787099A1 (en) | 2009-03-30 | 2010-10-14 | Anice C. Lowen | Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof |
| KR101790354B1 (ko) * | 2009-05-11 | 2017-10-25 | 얀센 백신스 앤드 프리벤션 비.브이. | 인플루엔자 바이러스 h3n2를 중화시킬 수 있는 인간 결합 분자 및 그것의 용도 |
| JP5941841B2 (ja) | 2009-05-26 | 2016-06-29 | アイカーン スクール オブ メディシン アット マウント サイナイ | 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用 |
| US9701723B2 (en) | 2010-02-18 | 2017-07-11 | Icahn School Of Medicine At Mount Sinai | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
| WO2011123495A1 (en) | 2010-03-30 | 2011-10-06 | Mount Sinai School Of Medicine | Influenza virus vaccines and uses thereof |
| US9707288B2 (en) | 2010-07-22 | 2017-07-18 | John W. Schrader | Cross-protective pathogen protection, methods and compositions thereof |
| WO2012018907A2 (en) | 2010-08-03 | 2012-02-09 | University Of Washington Through Its Center For Commercialization | Polypeptides for treating and/or limiting influenza infection |
| EP3699286A1 (en) | 2011-04-20 | 2020-08-26 | The Trustees of the University of Pennsylvania | Regimens and compositions for aav-mediated passive immunization of airborne pathogens |
| EP2731967B1 (en) | 2011-07-14 | 2016-10-12 | Janssen Vaccines & Prevention B.V. | Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses |
| EP2758075B1 (en) | 2011-09-20 | 2023-05-03 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
| CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
| WO2013059524A2 (en) * | 2011-10-18 | 2013-04-25 | Emory University | Antibodies directed against influenza |
| IN2014CN04742A (es) * | 2011-11-28 | 2015-09-18 | Crucell Holland Bv | |
| KR20130059721A (ko) * | 2011-11-29 | 2013-06-07 | (주)셀트리온 | 인간 b 세포에서 생산된 인플루엔자 a 바이러스 중화 활성을 가지는 결합 분자 |
| WO2013081463A2 (en) | 2011-12-02 | 2013-06-06 | Aimm Therapeutics B.V. | Influenza a virus specific antibodies |
| MX367743B (es) | 2011-12-05 | 2019-09-04 | Trellis Bioscience Llc | Anticuerpos utiles para la inmunizacion pasiva de influenza. |
| MX360056B (es) * | 2012-03-08 | 2018-10-19 | Janssen Vaccines & Prevention Bv | Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos. |
| EP2800576A2 (en) | 2012-03-13 | 2014-11-12 | University Of Washington Through Its Center For Commercialization | Polypeptides for treating and/or limiting influenza infection |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| EP2712626A1 (en) | 2012-09-28 | 2014-04-02 | Fabentech | Passive immunisation against influenza, in particular H5N1 |
| BR112015010817A8 (pt) | 2012-11-13 | 2018-01-23 | Genentech Inc | anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina |
| EP2934581B1 (en) | 2012-12-18 | 2022-09-14 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
| IL241552B2 (en) | 2013-03-14 | 2023-09-01 | Contrafect Corp | Preparation and methods based on neutralizing antibodies administered intranasally for increased therapeutic efficacy |
| EP2970397A2 (en) | 2013-03-14 | 2016-01-20 | University Of Washington Through Its Center For Commercialization | Polypeptides for treating and/or limiting influenza infection |
| US9908930B2 (en) | 2013-03-14 | 2018-03-06 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| US9649375B2 (en) | 2013-03-14 | 2017-05-16 | The Administrators Of The Tulane Educational Fund | Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith |
| KR20140118682A (ko) | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 a 바이러스 중화 결합 분자를 포함하는 조성물 |
| KR101511619B1 (ko) * | 2013-04-30 | 2015-04-13 | 한국생명공학연구원 | 개 인플루엔자 바이러스 h3n2의 ha1 단백질을 항원으로 포함하는 개 인플루엔자 바이러스 h3n2에 특이적인 혈청 진단용 키트 |
| CN105452270B (zh) | 2013-05-30 | 2020-12-01 | 扬森疫苗与预防公司 | 流行性感冒病毒疫苗及其用途 |
| RU2682049C2 (ru) * | 2014-01-27 | 2019-03-14 | Дженентек, Инк. | Лечение вируса гриппа а h7n9 |
| AU2015214146B2 (en) | 2014-02-04 | 2020-09-17 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
| US10639370B2 (en) | 2014-02-04 | 2020-05-05 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
| WO2015120474A1 (en) | 2014-02-10 | 2015-08-13 | Igm Biosciences, Inc. | Iga multi-specific binding molecules |
| WO2015143339A2 (en) | 2014-03-21 | 2015-09-24 | University Of Washington | Enhanced influenza hemagglutinin binders |
| KR101628331B1 (ko) * | 2014-03-28 | 2016-06-08 | 주식회사 녹십자엠에스 | 인플루엔자 a 바이러스 특이적 단클론 항체 및 이를 이용한 인플루엔자 감염 치료 및 진단 방법 |
| CR20160519A (es) | 2014-05-13 | 2017-01-27 | The Trustees Of The Univ Of Pennysylvania | Composiciones que comprenden avv que expresa constructos de anticuerpos duales y sus usos |
| WO2016005480A1 (en) | 2014-07-10 | 2016-01-14 | Crucell Holland B.V. | Influenza virus vaccines and uses thereof |
| KR102463632B1 (ko) | 2014-07-10 | 2022-11-03 | 얀센 백신스 앤드 프리벤션 비.브이. | 인플루엔자 바이러스 백신 및 이의 용도 |
| TWI701258B (zh) | 2014-12-19 | 2020-08-11 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| JP2018504412A (ja) | 2015-01-23 | 2018-02-15 | アイカーン スクール オブ メディシン アット マウント サイナイ | インフルエンザウイルスワクチン接種レジメン |
| US11135282B2 (en) * | 2015-04-08 | 2021-10-05 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
| WO2016200543A2 (en) | 2015-05-13 | 2016-12-15 | The Trustees Of The University Of Pennsylvania | Aav-mediated expression of anti-inluenza antibodies and methods of use thereof |
| WO2017083627A1 (en) | 2015-11-13 | 2017-05-18 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| CA3015347A1 (en) | 2016-02-24 | 2017-08-31 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
| EP3471767A4 (en) | 2016-06-15 | 2020-01-15 | Icahn School of Medicine at Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
| CN106146657B (zh) * | 2016-07-12 | 2020-07-17 | 晋明(天津)生物医药技术开发有限公司 | 广谱结合流感病毒a的重组抗体片段及其制备方法与应用 |
| RS65241B1 (sr) | 2017-02-28 | 2024-03-29 | Univ Pennsylvania | Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| TW201837170A (zh) | 2017-02-28 | 2018-10-16 | 賓州大學委員會 | 新穎aav媒介的流感疫苗 |
| WO2018187706A2 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
| WO2019076218A1 (zh) * | 2017-10-18 | 2019-04-25 | 厦门大学 | H3n2亚型流感病毒血凝素蛋白的突变体及其应用 |
| PL3743106T3 (pl) | 2018-01-23 | 2022-11-14 | Janssen Vaccines & Prevention B.V. | Szczepionki przeciwko wirusowi grypy i ich zastosowanie |
| SG11202006379UA (en) | 2018-01-26 | 2020-07-29 | Regeneron Pharma | Human antibodies to influenza hemagglutinin |
| WO2019246363A1 (en) | 2018-06-21 | 2019-12-26 | Icahn School Of Medicine At Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
| EP3946613A1 (en) | 2019-03-25 | 2022-02-09 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| WO2020219719A1 (en) | 2019-04-24 | 2020-10-29 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
| JP7865873B2 (ja) | 2019-09-05 | 2026-05-26 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | インフルエンザウイルスワクチン及びその使用 |
| EP4031558A4 (en) * | 2019-09-20 | 2023-05-31 | Academia Sinica | CHIMERIC HEMAGGLUTININ PROTEIN AND VACCINE COMPOSITION CONTAINING IT |
| CN115003328A (zh) | 2019-10-22 | 2022-09-02 | 西奈山伊坎医学院 | 重组神经氨酸酶及其用途 |
| CA3098079C (en) * | 2019-12-13 | 2023-06-20 | Autonomous Medical Devices Inc. | Apparatus and method for point-of-care, rapid, field-deployable diagnostic testing of covid-19, viruses, antibodies and markers |
| WO2021173965A1 (en) | 2020-02-28 | 2021-09-02 | Massachusetts Institute Of Technology | Identification of variable influenza residues and uses thereof |
| WO2021201677A1 (en) | 2020-04-01 | 2021-10-07 | Kiadis Pharma Intellectual Property B.V. | Compositions and methods targeting influenza |
| AR124216A1 (es) | 2020-12-01 | 2023-03-01 | Univ Pennsylvania | Composiciones nuevas con motivos selectivos específicos del tejido y composiciones que las contienen |
| JP2024515788A (ja) | 2021-04-27 | 2024-04-10 | ジェネレーション バイオ カンパニー | 治療抗体を発現する非ウイルスdnaベクター及びその使用 |
| EP4493212A1 (en) | 2022-03-14 | 2025-01-22 | Generation Bio Co. | Heterologous prime boost vaccine compositions and methods of use |
| EP4508077A4 (en) | 2022-04-14 | 2026-03-25 | Invisishield Tech Ltd | COMPOSITIONS FOR PREVENTING OR TREATMENT OF INFLUENZA INFECTIONS |
| US20260183380A1 (en) | 2022-11-14 | 2026-07-02 | Janssen Vaccines & Prevention B.V. | Influenza b virus vaccines and uses thereof |
| TW202527960A (zh) | 2023-09-06 | 2025-07-16 | 美商賽諾菲巴斯德公司 | 經修飾b型流感血球凝集素多肽及核酸及其用途 |
| WO2026027730A1 (en) | 2024-07-31 | 2026-02-05 | Sanofi | Modified h5 influenza hemagglutinin polypeptides and nucleic acids and uses thereof |
| WO2026052773A1 (en) | 2024-09-06 | 2026-03-12 | Sanofi | Modified influenza a hemagglutinin polypeptides and nucleic acids and uses thereof |
| CN119775398B (zh) * | 2024-12-03 | 2025-10-10 | 深圳市儿童医院 | 一种结合h3n2 ha蛋白的全人源单克隆抗体和应用 |
| CN119775400B (zh) * | 2024-12-03 | 2025-10-17 | 深圳市儿童医院 | 一种结合h3n2 ha蛋白的全人源单克隆抗体mz001和应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| NL9101953A (nl) | 1991-11-21 | 1993-06-16 | Seed Capital Investments | Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen. |
| US5624949A (en) | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| EP0934526B1 (en) | 1996-10-08 | 2003-01-08 | U-BISys B.V. | Methods and means for selecting peptides and proteins having specific affinity for a target |
| ES2378272T3 (es) | 1999-04-15 | 2012-04-10 | Crucell Holland B.V. | Producción de proteína recombinante en una célula humana |
| US7329530B2 (en) | 2001-06-15 | 2008-02-12 | Crucell Holland B.V. | Chimaeric phages |
| DE102004037820A1 (de) * | 2004-08-04 | 2006-03-16 | Epcos Ag | Elektrische Schaltung und Bauelement mit der Schaltung |
| NZ600075A (en) | 2005-12-09 | 2013-12-20 | Amc Amsterdam | Means and methods for influencing the stability of antibody producing cells |
| US8148085B2 (en) | 2006-05-15 | 2012-04-03 | Sea Lane Biotechnologies, Llc | Donor specific antibody libraries |
| JP2009537147A (ja) * | 2006-05-15 | 2009-10-29 | シー レーン バイオテクノロジーズ, エルエルシー | インフルエンザウイルスに対する中和抗体 |
| CA2663388C (en) | 2006-09-07 | 2017-01-17 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| JP5305427B2 (ja) * | 2007-01-11 | 2013-10-02 | 公立大学法人大阪府立大学 | インフルエンザウイルスに対する抗体の産生方法 |
| CN102046654A (zh) * | 2007-03-13 | 2011-05-04 | 胡马斯有限公司 | 针对甲型流感病毒h5n1株系的抗体 |
| US8383121B2 (en) * | 2007-09-13 | 2013-02-26 | Temasek Life Sciences Laboratory Limited | Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof |
| FR2921928B1 (fr) * | 2007-10-08 | 2011-03-04 | Sanofi Pasteur | Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal |
| EP3524619A1 (en) * | 2007-12-06 | 2019-08-14 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
| ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
| KR101790354B1 (ko) * | 2009-05-11 | 2017-10-25 | 얀센 백신스 앤드 프리벤션 비.브이. | 인플루엔자 바이러스 h3n2를 중화시킬 수 있는 인간 결합 분자 및 그것의 용도 |
-
2010
- 2010-05-06 KR KR1020117028080A patent/KR101790354B1/ko not_active Expired - Fee Related
- 2010-05-06 MX MX2011011331A patent/MX2011011331A/es unknown
- 2010-05-06 BR BRPI1012749-6A patent/BRPI1012749B1/pt not_active IP Right Cessation
- 2010-05-06 US US13/138,941 patent/US8470327B2/en active Active
- 2010-05-06 CN CN201080021000.XA patent/CN102448986B/zh active Active
- 2010-05-06 WO PCT/EP2010/056217 patent/WO2010130636A1/en not_active Ceased
- 2010-05-06 MY MYPI2011005400A patent/MY183517A/en unknown
- 2010-05-06 CA CA2761648A patent/CA2761648C/en active Active
- 2010-05-06 CN CN201510690863.0A patent/CN105418757B/zh active Active
- 2010-05-06 ES ES10718169T patent/ES2934102T3/es active Active
- 2010-05-06 JP JP2012510222A patent/JP5813629B2/ja active Active
- 2010-05-06 SG SG2011083011A patent/SG176003A1/en unknown
- 2010-05-06 NZ NZ596032A patent/NZ596032A/xx not_active IP Right Cessation
- 2010-05-06 EA EA201171383A patent/EA029939B8/ru not_active IP Right Cessation
- 2010-05-06 EP EP10718169.5A patent/EP2430046B1/en active Active
- 2010-05-06 AU AU2010247530A patent/AU2010247530B2/en not_active Ceased
- 2010-05-10 TW TW099114829A patent/TWI589300B/zh not_active IP Right Cessation
- 2010-05-11 AR ARP100101631A patent/AR076570A1/es not_active Application Discontinuation
-
2011
- 2011-11-08 IL IL216222A patent/IL216222A/en active IP Right Grant
- 2011-11-11 CU CU2011000206A patent/CU23938B1/es active IP Right Grant
-
2013
- 2013-05-20 US US13/897,843 patent/US9611317B2/en active Active
-
2015
- 2015-09-16 JP JP2015182540A patent/JP2016040261A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20110206A7 (es) | Moléculas de unión humanas capaces de neutralizar el virus de la influenza h3n2 | |
| MX360056B (es) | Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos. | |
| MX346206B (es) | Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b. | |
| MD20140035A2 (ro) | Metodă de tratament al hepatitei virale C | |
| AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
| UY33897A (es) | Inhibidores del virus de la hepatitis c | |
| AR084237A1 (es) | Metodos para tratar virus de hepatitis c (hcv), composicion | |
| MX2018003198A (es) | Moduladores de proteínas básicas de la hepatitis b. | |
| CL2014003634A1 (es) | Inhibidores del virus de la hepatitis c | |
| EA201500854A1 (ru) | Композиция, содержащая по меньшей мере две связывающие молекулы, нейтрализующие вирус гриппа а | |
| EA201791460A1 (ru) | N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения | |
| EA201590703A1 (ru) | Ингибиторы mek при лечении вирусных заболеваний | |
| ECSP14013315A (es) | Inhibidores de aplicación viral | |
| BR112016020688A2 (pt) | Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc) | |
| MX350282B (es) | Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas. | |
| UY34066A (es) | Inhibidores del virus de la hepatitis c | |
| CR20160178A (es) | Derivados de desoxinojirimicina y sus métodos de uso | |
| UY32715A (es) | Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados | |
| UY32720A (es) | Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados | |
| BR112017004197A2 (pt) | composições de vacina contra doenças do vírus da dengue | |
| EA201491581A1 (ru) | Везикулярные композиции | |
| EA201790771A1 (ru) | Фармацевтические композиции длительного действия для лечения гепатита c | |
| EA201790776A1 (ru) | Комбинированные композиции длительного действия и способы лечения гепатита с | |
| MX343198B (es) | Moleculas de union humanas capaces de neutralizar el virus de la influenza h5n1 y usos de las mismas. | |
| TR201910305T4 (tr) | Viral enfeksiyonları tedavi etmek için bileşikler. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant of patent |